| Literature DB >> 30121202 |
Seyed Mojtaba Ghiasi1, Mattias Salling Dahllöf1, Yama Osmai1, Mirwais Osmai1, Kathrine Kronberg Jakobsen1, Alexander Aivazidis2, Björn Tyrberg2, Lisa Perruzza3, Michala Cecilie Burstein Prause1, Dan Ploug Christensen1, Morten Fog-Tonnesen4, Morten Lundh1, Fabio Grassi3, Lucienne Chatenoud5, Thomas Mandrup-Poulsen6.
Abstract
β-Cells may be a source of IL-1β that is produced as inactive pro-IL-1β and processed into biologically-active IL-1β by enzymatic cleavage mediated by the NLRP1-, NLRP3- and NLRC4-inflammasomes. Little is known about the β-cell inflammasomes. NLRP1-expression was upregulated in islet-cells from T2D-patients and by IL-1β+IFNγ in INS-1 cells in a histone-deacetylase dependent manner. NLRP3 was downregulated by cytokines in INS-1 cells. NLRC4 was barely expressed and not regulated by cytokines. High extracellular K+ reduced cytokine-induced apoptosis and NO production and restored cytokine-inhibited accumulated insulin-secretion. Basal inflammasome expression was JNK1-3 dependent. Knock-down of the ASC interaction domain common for NLRP1 and 3 improved insulin secretion and ameliorated IL-1β and/or glucolipotoxicity-induced cell death and reduced cytokine-induced NO-production. Broad inflammasome-inhibition, but not NLRP3-selective inhibition, protected against IL-1β-induced INS-1 cell-toxicity. We suggest that IL-1β causes β-cell toxicity in part by NLRP1 mediated caspase-1-activation and maturation of IL-1β leading to an autocrine potentiation loop.Entities:
Keywords: ASC; Danger associated-molecular patterns; Inflammation; Potassium; Purinergic receptors
Mesh:
Substances:
Year: 2018 PMID: 30121202 DOI: 10.1016/j.mce.2018.08.001
Source DB: PubMed Journal: Mol Cell Endocrinol ISSN: 0303-7207 Impact factor: 4.102